A highlight of this study is that the altered distribution of CLDN1 and OCLN that we observed upon TACSTD2 gene silencing in vitro is analogous to the pattern that we documented in vivo in primary liver tissues from patients with HCV-associated HCC, where HCV replication is severely restricted. Here, TACSTD2 is linked to hepatocellular carcinoma.